BEAM - Beam Therapeutics Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
60,920
60,920
51,844
24
18
Operating expenses
Research development
311,594
311,594
387,087
103,179
54,619
Selling general and administrative
87,805
87,805
57,222
29,605
20,553
Total operating expenses
399,399
399,399
444,309
132,784
75,172
Operating income or loss
-338,479
-338,479
-392,465
-132,760
-75,154
Interest expense
-
-
-
-
187
Total other income/expenses net
63,004
63,004
21,836
-63,400
-5,471
Income before tax
-260,178
-260,178
-370,638
-194,592
-78,326
Income tax expense
3,410
3,410
-
-
-
Income from continuing operations
-289,088
-289,088
-370,638
-194,592
-78,326
Net income
-289,088
-289,088
-370,638
-194,592
-78,326
Net income available to common shareholders
-289,088
-289,088
-370,638
-195,869
-91,040
Basic EPS
-
-4.13
-5.77
-4.19
-2.01
Diluted EPS
-
-4.13
-5.77
-4.19
-2.01
Basic average shares
-
70,015
64,228
46,733
45,325
Diluted average shares
-
70,015
64,228
46,733
45,325
EBITDA
-
-338,479
-392,465
-128,025
-74,636